Goodwin: Generate Biomedicines Completes $370 Million Series B
November 19, 2021
November 19, 2021
BOSTON, Massachusetts, Nov. 19 -- Goodwin, a law firm, issued the following news release on Nov. 18, 2021:
The Life Sciences team advised Generate Biomedicines in the completion of its $370 million Series B financing to advance the development of its novel drug generation platform.
The financing round included the company's founder, Flagship Pioneering, along with several institutional co-investors, including: a wholly-owned subsidiary of the Abu Dhabi Investment A . . .
The Life Sciences team advised Generate Biomedicines in the completion of its $370 million Series B financing to advance the development of its novel drug generation platform.
The financing round included the company's founder, Flagship Pioneering, along with several institutional co-investors, including: a wholly-owned subsidiary of the Abu Dhabi Investment A . . .